Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy resistant L858R/T790M/C797S mutant
Prof. Dr. Stefan Laufer, Eberhard-Karls-Universität Tübingen
Published in: Angew. Chem. Int. Ed. 55, 10890
The development of new and better medication takes place largely in the pharmaceutical industry. Ideally the translation of fundamental research into clinical application is highly effective. However, in reality there is a divide that is difficult to overcome – in science it is called the “Valley of Death”. Many potential new active ingredients lay victim to this chasm for the most diverse reasons. Interdisciplinary research approaches and cooperations are critical for the translation of basic science into pharmaceutical application. The team led by Prof. Dr. Stefan Laufer has developed a novel EGFR inhibitor with anti-tumour properties, with the special characteristic that the active ingredient displays strong biological activity, even after EGFR mutation as occurs in patients that have developed resistances. The active ingredient therefore appears to be “resistance resistant” to a certain extent.